MedTrace Logo

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2024-08-06

No results posted yet for this study

Summary

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.

Conditions

  • Uveitis, Posterior

Interventions

DRUG

Fluocinolone Acetonide Intravitreal Implant 0.18 mg

YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.

Sponsors & Collaborators

  • CBCC Global Research

    collaborator NETWORK

  • Alimera Sciences

    lead INDUSTRY

Principal Investigators

  • Antonio Cutino · Alimera Sciences Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2025-11-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322070 on ClinicalTrials.gov